How likely are you to recommend Redeye to a friend or colleague?
1
2
3
4
5
6
7
8
9
10
Not likely
Very likely
Not likely
1
2
3
4
5
6
7
8
9
10
Very likely
Message received
Thanks again for rating us!
SEARCH
LIDDS: Another (potential) weapon against cancer
JS
Jakob Svensson
2019-04-23
05:30
Earlier in April LIDDS announced a new project, a Toll-Like Receptor 9 (TLR9) formulated with the NanoZolid platform. Positive preclinical data have been generated so far and LIDDS aims to start Phase I in 2020. We have included the new project in our valuation which raising our valuation range slightly.